Who is sponsoring NCT00347971?

NCT00347971 is sponsored by ZymoGenetics.

What condition does NCT00347971 study?

NCT00347971 studies Lymphoma, Non-Hodgkin.

What drugs are being tested in NCT00347971?

Interventions: recombinant human interleukin 21 and rituximab.

What is the status of NCT00347971?

NCT00347971 is currently COMPLETED.

Last reviewed 2008-09-04 · How we verify

Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered in Combination With Rituxan (Rituximab) in Subjects With B-Cell Non Hodgkin's Lymphoma

NCT00347971 Phase 1 COMPLETED

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

Details

Lead sponsor	ZymoGenetics
Phase	Phase 1
Status	COMPLETED
Enrolment	23
Start date	2006-06
Completion	2008-04

Conditions

Lymphoma, Non-Hodgkin

Interventions

recombinant human interleukin 21 and rituximab

Primary outcomes

Incidence and severity of adverse events through 1 month after completing treatment — During treatment and through 1 month after completing treatment
Incidence and grade of clinical laboratory abnormalities through 1 month after treatment — During treatment and through 1 month after completing treatment

Countries

United States